Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …

Molecular dynamics (MD) simulations have become increasingly useful in the modern drug
development process. In this review, we give a broad overview of the current application …

KRAS is the most frequently mutated oncogene in human cancer. In addition to holding this
distinction, unsuccessful attempts to target this protein have led to the characterization of …

One of the most common drivers in human cancer is the mutant KRAS protein. Not so long
ago KRAS was considered as an undruggable oncoprotein. After a long struggle, however …

The mechanism by which the wild-type KRAS allele imparts a growth inhibitory effect to
oncogenic KRAS in various cancers, including lung adenocarcinoma (LUAD), is poorly …

Ras proteins are classical members of small GTPases that function as molecular switches by
alternating between inactive GDP-bound and active GTP-bound states. Ras activation is …

RAS GTPases are important mediators of oncogenesis in humans. However,
pharmacological inhibition of RAS has proved challenging. Here we describe a functionally …

K-Ras is targeted to the plasma membrane by a C-terminal membrane anchor that
comprises a farnesyl-cysteine-methyl-ester and a polybasic domain. We used quantitative …

The extracellular-regulated kinases ERK1 and ERK2 are evolutionarily conserved,
ubiquitous serine–threonine kinases that are involved in regulating cellular signaling in both …

One of the open questions in RAS biology is the existence of RAS dimers and their role in
RAF dimerization and activation. The idea of RAS dimers arose from the discovery that RAF …